NBCUniversal considering to launch a sports cable network, WSJ reports
The potential channel, which would be offered in specialized packages, could debut as early as the fall, the report said, citing people familiar with the matter.
According to the report, the proposed channel would primarily feature sports that are also streamed on NBCUniversal's Peacock streaming platform.
The network would be offered to cable and satellite providers as part of specialty channel packages, the report added.
Talks remain at an early stage and a final decision regarding the launch of the network has not yet been made, WSJ said.
NBCUniversal declined to comment on the report.
The news stands in stark contrast to the broader challenges of the industry, as traditional television continues to lose ground to the rise of on-demand content and the growing trend of cord-cutting. However, live sports remain a bright spot, thriving even as other segments struggle.
Meanwhile, NBCU is moving forward with plans to spin off most of its cable networks into a new company, signaling a significant shift in its media strategy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Chicago Cubs lose a franchise icon with the death of Ryne Sandberg
MILWAUKEE — The baseball world mourned Monday, when Cubs Hall of Fame second baseman Ryne Sandberg died at the age of 65 after a battle with cancer, the team announced. He was diagnosed with metastatic prostate cancer in 2024. Over 16 MLB seasons, 15 of them with the Cubs, Sandberg hit .285 with 282 homers and 1,061 RBI. He won seven Silver Slugger Awards, nine Gold Glove Awards and the 1984 MVP award to go with 10 All-Star appearances. In 2005, he was inducted into the Baseball Hall of Fame in Cooperstown. There is a statue of him outside Wrigley Field, his No. 23 is one of only four numbers retired by the Cubs, and the man known as 'Ryno' is an unquestioned franchise icon. 'Ryne Sandberg was a hero to a generation of Chicago Cubs fans and will be remembered as one of the all-time greats in nearly 150 years of this historic franchise,' Cubs chairman Tom Rickets said in a statement. Sandberg actually began his career with the Philadelphia Phillies. He played 13 games at shortstop for the Phillies in 1981 before he was traded to the Cubs in the offseason, along with then-shortstop and future manager and executive Larry Bowa. Sandberg, who moved to second base once he arrived in Chicago, then spent the 1982 through 1997 — he retired in 1994 but rejoined the Cubs in '96 — seasons on the North Side. The first two seasons of his Cubs career were solid, but the legend of Sandberg really took shape in 1984. His unique combination of size, speed and power separated him from other second basemen and made him one of the most impactful hitters in baseball. And on June 23, 1984, Sandberg became a household name. In what is now referred to as 'The Sandberg Game,' the Cubs' second baseman hit game-tying homers in the ninth and 10th innings off Cardinals closer Bruce Sutter in a game in which the Cubs came back from three different deficits. From that day on, there was no mistaking who the best player in baseball was. Sandberg finished the 1984 season batting .314 with 200 hits, 36 doubles, 19 triples, 19 home runs and 32 stolen bases. He won the Gold Glove at second base and took home the NL MVP Award that fall. Beginning that season, he made 10 consecutive All-Star appearances. [Get more Chicago news: Cubs team feed] While Sandberg's career was defined by his excellence at the plate, he was also one of the game's best defenders. His career .989 fielding percentage was a major-league record at second when he retired. The nine Gold Glove Awards he won over the course of his career are second all time for a second baseman, behind only Roberto Alomar's 10, and his seven Silver Slugger Awards are tied with Jose Altuve for the most by a second baseman. Following his playing career, Sandberg coached in the minor leagues for the Cubs and Phillies, managed the Phillies for parts of three seasons and then rejoined the Cubs as a goodwill ambassador and occasional color commentator.
Yahoo
23 minutes ago
- Yahoo
Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings
Medical technology company Hologic (NASDAQ:HOLX) will be reporting earnings this Wednesday afternoon. Here's what investors should know. Hologic met analysts' revenue expectations last quarter, reporting revenues of $1.01 billion, down 1.2% year on year. It was a slower quarter for the company, with a slight miss of analysts' full-year EPS guidance estimates and full-year revenue guidance meeting analysts' expectations. Is Hologic a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Hologic's revenue to be flat year on year at $1.01 billion, slowing from the 2.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.05 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hologic has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 0.9% on average. Looking at Hologic's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. Hologic is up 2.8% during the same time and is heading into earnings with an average analyst price target of $69.93 (compared to the current share price of $66.99). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
CONMED (CNMD) Q2 Earnings: What To Expect
Medical tech company CONMED (NYSE:CNMD) will be announcing earnings results this Wednesday after market close. Here's what to look for. CONMED beat analysts' revenue expectations by 2.6% last quarter, reporting revenues of $321.3 million, up 2.9% year on year. It was a very strong quarter for the company, with a solid beat of analysts' full-year EPS guidance estimates and an impressive beat of analysts' EPS estimates. Is CONMED a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting CONMED's revenue to grow 1.9% year on year to $338.3 million, slowing from the 4.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.12 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. CONMED has missed Wall Street's revenue estimates three times over the last two years. Looking at CONMED's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. CONMED is down 4% during the same time and is heading into earnings with an average analyst price target of $66.60 (compared to the current share price of $50.02). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
